Evotec, Halozyme

San Diego’s Halozyme withdraws $2.1B Evotec bid, just one week after making offer
San Diego biotech firm Halozyme Therapeutics is walking back its proposed $2.1 billion acquisition of Evotec, saying the German drugmaker doesn’t want to be bought. The local company announced Friday morning at 5:35 a.
Halozyme gains after withdrawing Evotec bid
Shares of Halozyme Therapeutics (NASDAQ:HALO) added ~12% in the premarket on Friday after the drug delivery technology company withdrew its non-binding proposal to acquire German drugmaker Evotec SE (NASDAQ:EVO).
Halozyme withdraws $2B bid for Evotec after German biotech was 'unwilling to engage'
Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to engage with us to explore a potential combination,” Halozyme president and CEO Helen Torley said in a Nov. 22 release.
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share in cash,
Evotec falls 21% to $4.20 after Halozyme withdraws acquisition proposal
Halozyme (HALO) is up 11% to $50.99 in pre-market trading.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks
BRIEF—Halozyme withdraws non-binding offer for Evotec
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash.
San Diego biotech Halozyme makes $2.1B bid for German drugmaker
Halozyme Therapeutics, a San Diego-based biopharmaceutical company, has made a $2.1 billion bid to buy German drugmaker Evotec.
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley. Most Read from BloombergSaudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency SaceThe Urban-Rural Divide Over Highway Expansion and Emissions“We feel confident in being able to fund this as a fully cash deal,
Halozyme withdraws $2.1 billion buyout offer for German drug developer Evotec
Halozyme Therapeutics has pulled its proposal to buy Evotec SE for 2 billion euros ($2.09 billion) as the German drug developer was unwilling to engage in discussions, the U.S. firm said on Friday. Shares of Halozyme rose 4.
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery
The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc ...
Halozyme’s Transformative Acquisition of Evotec: A Strategic Move for Growth and Market Expansion
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report), with a price ...